NutriBand (NTRB) Non-Current Assets (2017 - 2026)
NutriBand (NTRB) posted Non-Current Assets of $2.5 million for Q2 2026, down 1.69% sequentially from $2.6 million in Q1 2026, and down 7.58% YoY from $2.7 million in Q2 2025.
NutriBand (NTRB) Non-Current Assets (2017 - 2026) Analysis & Trends
NutriBand has reported Non-Current Assets for 10 years, with the latest figure at $2.5 million in Q2 2026.
- Quarterly Non-Current Assets fell 7.58% year-over-year to $2.5 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $10.3 million (down 43.01% YoY) and the FY2026 annual result came in at $2.6 million, down 4.35% from the prior year.
- Non-Current Assets eased to $2.5 million in Q2 2026 per NTRB's latest filing, from $2.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $7.3 million in Q2 2022 and troughed at $2.5 million in Q2 2026.
- A 5-year average of $5.4 million and a median of $6.5 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets slipped 2.63% in 2024, then slumped 59.0% in 2025.
- Over 5 years, Non-Current Assets stood at $7.2 million in 2022, then retreated by 8.92% to $6.5 million in 2023, then decreased by 2.63% to $6.4 million in 2024, then plunged by 59.0% to $2.6 million in 2025, then fell by 3.38% to $2.5 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $2.5 million, $2.6 million, and $2.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | NutriBand | 57.74 Mn | 53.73 Mn | 196,801.00 | 2.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 2.52 Mn |
| Jan 31, 2026 | 2.56 Mn |
| Oct 31, 2025 | 2.60 Mn |
| Jul 31, 2025 | 2.66 Mn |
| Apr 30, 2025 | 2.72 Mn |
| Jan 31, 2025 | 2.68 Mn |
| Oct 31, 2024 | 6.35 Mn |
| Jul 31, 2024 | 6.39 Mn |
| Apr 30, 2024 | 6.42 Mn |
| Jan 31, 2024 | 6.50 Mn |
| Oct 31, 2023 | 6.52 Mn |
| Jul 31, 2023 | 6.60 Mn |
| Apr 30, 2023 | 6.68 Mn |
| Jan 31, 2023 | 6.76 Mn |
| Oct 31, 2022 | 7.16 Mn |
| Jul 31, 2022 | 7.27 Mn |
| Apr 30, 2022 | 7.34 Mn |
| Jan 31, 2022 | 7.27 Mn |
| Oct 31, 2021 | 9.48 Mn |
| Jul 31, 2021 | 9.56 Mn |